Histological analysis to determine TIL levels can inform decision-making, and part of the reason combination therapies have been successful is because immunotherapies can themselves alter the composition of cells infiltrating the tumor: blocking CTLA-4 in particular elicits an increase in COS+ Th1-like CD4 effector cells in the TME [146]. This evidence concerns the gene CD4 and neoplasm.